The story of pentadecanoic acid, the odd-chain saturated fatty acid now sold as Fatty15, begins not in a human clinical trial but in a Navy dolphin research program in San Diego. Researcher Dr. Stephanie Venn-Watson noticed something unusual: dolphins moved onto a modified fish diet had lower insulin and cholesterol and recovered from chronic anemia.[1] That observation set off a decade-long scientific investigation that would eventually challenge long-standing assumptions about saturated fat and cellular health.
What emerged from that research is a hypothesis still being actively tested: that C15 (pentadecanoic acid), a 15-carbon odd-chain saturated fatty acid found naturally in full-fat dairy and the fat of ruminant animals, may play a meaningful role in supporting cell membrane stability, mitochondrial function, and metabolic signaling in humans. The findings described below are drawn from the peer-reviewed literature on C15, much of it published by the research team that first identified it; every study referred to is listed in the References section at the end of this article. This article is informational only and does not constitute medical advice.
Key Takeaways
- C15 (pentadecanoic acid) emerged as a candidate health-relevant fatty acid from studies of Navy dolphins: an earlier study pointed to the related C17:0, and a later metabolomics study ranked C15 highest among the odd-chain fats. It did not come from a pre-planned human trial.
- The discovery path (pattern first, mechanism second) is unusual in nutrition science, but the signal came from a small animal cohort studied by authors with a pending patent, so it is a lead that needs careful experimental follow-up [2].
- Proposed mechanisms include cell membrane stabilization, partial PPAR-alpha/delta agonism, and potential reduction of ferroptosis and cellular senescence: all plausible but not yet confirmed in large human studies.
- The classification of C15 as an ‘essential’ fatty acid is a hypothesis by Epitracker researchers and has not been formally adopted by regulatory or mainstream scientific bodies.
- The first randomized trial of C15 alone (200 mg a day for 12 weeks) reported no significant adverse events, but larger independent studies are needed before clinical recommendations can be made.
The Navy Marine Mammal Program and an Unexpected Clue
Dr. Venn-Watson spent years working with the U.S. Navy Marine Mammal Program, which maintains a population of bottlenose dolphins used for sonar and underwater research tasks. Because these dolphins receive regular veterinary monitoring, researchers accumulated unusually rich longitudinal health data across a large cohort: a rare resource in animal research.
The dolphin clue was about C17:0, and it came from small animal groups
49 bottlenose dolphins
30 with higher insulin and 19 with lower insulin.
Lower C17:0 with higher insulin
Serum C17:0 was 0.3% in the higher-insulin group and 1.3% in the lower-insulin group.
Six dolphins fed extra fish
Over 24 weeks, daily C17:0 intake went from 400 to 1700 mg. Serum C17:0 rose and high ferritin fell, which was not seen in four reference dolphins.
The fat measured was C17:0
These results are for the related fat C17:0, not C15:0.
The dolphin work is a lead for researchers, not proof that C15 helps people.
Bottlenose dolphins in a Navy program; not a human trial. Source: PLoS ONE 2015.
Chart: c15hub.com: The dolphin clue was about C17:0, and it came from small animal groups
Embed this chart
Free to reuse on your site. Copy the code below; please keep the credit link.
The first lead was not C15. A 2015 PLoS One study compared two Navy dolphin groups with higher (n = 30) and lower (n = 19) mean insulin and found that the lower-insulin group had more serum heptadecanoic acid (C17:0), 1.3 percent versus 0.3 percent. Capelin, common in the higher-insulin group’s diet, had no detectable C17:0, while pinfish and mullet did. When six higher-insulin dolphins were fed a modified diet adding 25 percent pinfish and/or mullet for 24 weeks, serum C17:0 rose, high ferritin fell and blood-based metabolic syndrome indices normalized toward reference levels; four reference dolphins did not change. The authors disclosed a pending Navy patent licensed to a company owned by the lead author, and proposed that people’s move away from whole-fat dairy might contribute to low C17:0 and metabolic syndrome.[2] That is an observational signal plus a small feeding study of six animals, not proof of anything.
A 2016 follow-up on the same kind of diet shift reported that total serum adiponectin rose from 776 to 1196 pmol/ml over 24 weeks, along with increases in sphingosine-related lipids that the authors read as consistent with an insulin-sensitizing profile. Insulin sensitivity itself was not measured directly.[3] C15 entered the story with the 2020 metabolomics study: 20 dolphins on a modified diet were compared with 10 on a baseline diet over six months. The modified-diet dolphins had lower insulin (7.5 versus 14.8 μIU/ml), lower cholesterol (160 versus 186 mg/dl) and higher hematocrit by month 1, and dolphins that had been anemic had normal hemoglobin by month 3. Ten of the 25 prioritized lipids contained odd-chain saturated fatty acids, C15:0 was the highest-prioritized of them, and erythrocyte C15:0 rose from 1.5 to 5.8 μg/ml and independently predicted higher hemoglobin. The author called for further studies of whether odd-chain fatty acids actively attenuate anemia.[1]
Metabolomics: Finding the Signal in the Noise
Metabolomics is the large-scale study of small molecules, metabolites, present in biological samples like blood or tissue. It does not start with a hypothesis about a specific compound; instead, it scans broadly for patterns, asking which metabolites differ systematically between healthier and less healthy subjects. This unbiased approach is what made the dolphin research productive.
Research note: In this dolphin study, butter had the highest C17:0 of the off-the-shelf dairy products tested (423 mg per 100 g) and nonfat dairy had none detectable [2].
When the team applied metabolomic analysis to dolphins on the modified diet, a panel of 30 prioritized metabolites perfectly separated the two diet groups, and C15 was the highest-prioritized odd-chain fatty acid among the lipids involved.[1] Odd-chain fatty acids come largely from the diet, although some can also be made in the body, for example from propionic acid produced by gut bacteria, so the finding pointed toward dietary fat composition as one variable worth investigating rather than the only one.[4]
This metabolomics-first approach distinguished the C15 discovery from most nutrient research, which typically begins with a mechanistic hypothesis and then designs experiments around it. Here, the pattern in real-world biological data came first, which proponents argue makes the initial signal more credible, though it also means the causal direction still requires rigorous experimental confirmation.
Translating the Finding to Humans: Epidemiology and Early Trials
After identifying C15 as a candidate in dolphins, the Epitracker team asked whether the same association appeared in humans. They analyzed existing epidemiological datasets and found that circulating C15 levels in human blood were associated with various health markers, including metabolic and cardiovascular indicators, in directions consistent with the dolphin findings.[5]
Importantly, blood C15 is only weakly to moderately linked to dairy intake, but dairy is its richest food source, and full-fat dairy and ruminant fat had been broadly discouraged for decades under prevailing saturated-fat guidelines [17][18][19][20]. The researchers proposed that this dietary discouragement may have inadvertently reduced population-level C15 intake, and that the resulting decline in circulating C15 could be one underappreciated factor in modern metabolic health trends. This is a hypothesis, not an established causal claim.
Small human intervention studies have since examined supplemental C15 at doses in the low hundreds of milligrams per day. In one randomized controlled trial run at the University of California San Diego and supported by Seraphina Therapeutics, which supplied the capsules, 30 young adults [6] with overweight or obesity took 200 mg of C15 or placebo daily for 12 weeks; circulating C15 rose significantly and no significant adverse events were reported, though the trial was both short and small.[6] Larger, longer, independently replicated trials are needed before strong conclusions can be drawn about clinical benefit.
Why C15 Went Unnoticed, and What the Human Cohorts Found
Part of the reason C15 took so long to draw attention is that scientists mostly used it as a tool. Odd-chain saturated fatty acids were historically used as internal standards in chromatography methods because their concentrations in humans were assumed to be insignificant.[7] A 2024 Biochimie mini-review describes C15 as neglected in the literature until the last decade, when it moved from being a biomarker of dairy fat intake to a fatty acid studied for its own effects.[8]
Three large human analyses shaped that shift, all observational. In the European EPIC-InterAct case-cohort study (12,403 incident type 2 diabetes cases), plasma phospholipid C15 was inversely associated with type 2 diabetes (hazard ratio 0.79 per standard deviation, 95% CI 0.73 to 0.85), while even-chain saturated fats such as palmitic acid were positively associated (1.26).[9] A pooled analysis of 16 prospective cohorts in 12 countries (63,682 participants, 15,180 incident cases) reported a hazard ratio of 0.80 (95% CI 0.73 to 0.87) across the 10th-to-90th-percentile range of C15.[10] In 4,150 Swedish adults followed for a median of 16.6 years, higher serum C15 was associated with lower cardiovascular risk (hazard ratio 0.75 per interquintile range), and a meta-analysis of 18 observational studies found higher C15 and C17 linked to lower total cardiovascular disease; the authors note that single baseline measurements can misclassify exposure and that causality needs clinical and experimental testing.[11]
Later cohort work is less supportive of a causal heart benefit. In the CARDIA and ARIC cohorts, plasma C15 was not associated with incident cardiovascular disease, Mendelian randomization found no evidence that C15 causally affects blood pressure, and the authors concluded the evidence is not consistent with a causal cardiovascular benefit. An umbrella review also graded the C15 and diabetes evidence only suggestive (class III) [21][22].
Because blood C15 only partly tracks dairy fat (a meta-analysis found r = 0.33 with dairy fat and r = 0.20 with total dairy intake), these studies cannot easily separate the fatty acid from the foods that carry it [17]. A narrative review of dairy fat biomarkers adds that the evidence linking dairy fatty acids to cardiometabolic risk markers is mostly observational and that well-controlled dose-response intervention studies are lacking.[12]
There is also a live disagreement about where circulating C15 comes from. One review notes that C15 and C17 can be synthesized in the body, for example from gut-derived propionic acid.[4] Another points to alpha-oxidation as a possible route and observes that the C15-to-C17 ratio in human plasma is about 1 to 2, whereas dairy fat contains roughly the reverse, which hints that not all of it comes from food.[7] The 2024 Biochimie review, by contrast, says C15 might qualify as essential but that further investigation is needed on whether the body makes enough of it and whether it is truly required, and calls its essentiality controversial [8].[8] The question is not settled, and it is central to whether C15 can be called essential.
Proposed Mechanisms: Why C15 Might Matter at the Cellular Level
The Epitracker researchers have proposed several mechanisms by which C15 could influence cellular health. First, unlike even-chain saturated fatty acids, C15 is thought to integrate into cell membranes in a way that supports membrane stability and fluidity without the rigidity associated with longer even-chain saturates.[13] A more stable, well-composed cell membrane may support better cellular signaling and resilience.
Second, C15 has been characterized in laboratory studies as a partial agonist of PPAR-alpha and PPAR-delta receptors: nuclear receptors involved in fat metabolism, mitochondrial biogenesis, and inflammatory regulation.[14] If confirmed in human physiology at physiologically relevant concentrations, this pathway could help explain potential metabolic and anti-inflammatory effects.[15] It is worth emphasizing that receptor binding data from cell culture does not automatically translate into equivalent effects in the complexity of a living human body.
Third, the researchers have proposed that C15 may help reduce two cellular aging processes: ferroptosis (a form of iron-mediated cell death linked to oxidative stress) and cellular senescence (the accumulation of non-dividing, pro-inflammatory ‘zombie cells’).[13] These are active and legitimate areas of aging biology research, but direct evidence that dietary C15 at supplement doses meaningfully affects these processes in humans remains preliminary.
Later Dolphin Work: Brain Aging
A 2025 study returned to the Navy dolphins to look at the brain. Using 68 tissues from the archived brains of 19 dolphins, the authors found amyloid-beta plaques and markers of neuroinflammation, with the highest plaque density variation in the hippocampus (90th percentile of 4.95 plaques per mm2) and plaque density increasing with age (p = 0.05). Separately, in a third-party screening panel, C15 inhibited two enzymes relevant to cognitive health, fatty acid amide hydrolase (IC50 2.5 µM) and monoamine oxidase B (IC50 19.4 µM). The authors concluded that C15 may play a distinct role in supporting cognitive health. Two cautions apply: the enzyme work was done in vitro, not in the dolphins or in people, and the lead author is a co-founder of the company that holds exclusive licensing rights to commercialize odd-chain fatty acids. No conclusion about C15 and Alzheimer’s disease in humans can be drawn from it.[16]
The 'Essential Fatty Acid' Claim: What It Means and What It Doesn't
Venn-Watson and colleagues have proposed C15 as a newly essential fatty acid, which would make it the first addition to a list that has held only linoleic and alpha-linolenic acid. The proposal drew wide media attention. The term ‘essential’ in nutrition science has a specific meaning: a nutrient the body cannot synthesize in adequate amounts and must therefore obtain from food. The existing recognized essential fatty acids are the omega-6 linoleic acid and the omega-3 alpha-linolenic acid.
The Epitracker team’s argument rests on the observation that mammals have limited capacity to synthesize odd-chain fatty acids endogenously, making dietary intake the primary source. However, it is important to be clear that this ‘essential’ classification is a hypothesis advanced by the researchers themselves and has not been formally adopted by the FDA, the European Food Safety Authority, or mainstream nutrition science bodies. Peer debate continues, and some researchers question whether the observed associations rise to the level required to designate a nutrient as dietary-essential.
Fatty15, the supplement commercialized by Epitracker, delivers purified C15 as a single-ingredient capsule. The FDA has not evaluated Fatty15 for the treatment or prevention of any disease, and the supplement is marketed under general wellness claims rather than therapeutic ones.
Where the Science Stands Today and What Comes Next
As of the mid-2020s, the C15 research base consists of the original dolphin metabolomics work, human epidemiological analyses, in vitro mechanistic studies, and a small number of short human trials. This is a meaningful body of early-stage evidence, but it occupies the exploratory end of the evidence pyramid. The research has not yet produced the large, multi-site, long-duration randomized controlled trials that regulatory agencies and clinical guidelines require before making treatment recommendations.
Independent replication is the next critical step. Much of the published C15 research to date has been conducted by or in close collaboration with the Epitracker team, which has both a scientific and commercial interest in the outcome. Independent labs testing the same hypotheses, and ideally disagreeing publicly when the data warrant it, will be essential to establishing C15’s place in mainstream nutrition science.
For consumers, the discovery story is genuinely interesting and the proposed mechanisms are biologically plausible. In the one small randomized trial of C15 alone (30 adults, 200 mg a day for 12 weeks, industry-supported), no significant adverse events were reported; long-term safety is unknown [6]. Whether it delivers meaningful health benefits beyond a well-balanced diet remains an open question that ongoing research is working to answer.
🛒 Where to Buy Pentadecanoic Acid (C15)
- Fatty15 (official site) 20% off with code SFKKDBQQ
capsules, 100 mg C15 per capsule; 1 capsule/day starter, 2 capsules/day maintenance: Category creator, from the original Epitracker research team (Venn-Watson et al.); uses a patented, sustainably-sourced pure C15 ingredient; most expensive per-capsule but reference product for all comparisons - Double Wood Supplements Pentadecanoic Acid C15
capsules, 200 mg C15 per serving (2 capsules): Generic C15 supplement; significantly lower price than Fatty15; no independent clinical trials on this specific product; good option for budget-conscious buyers who want to trial the fatty acid - Sports Research Pentadecanoic Acid C15
softgels, 100 mg C15 per softgel: Established supplement brand with strong Amazon presence; softgel form may aid fat-soluble absorption; competitively priced mid-tier option - BulkSupplements Pentadecanoic Acid Powder (C15)
powder, 100 to 300 mg per measured serving: Most economical option for higher-dose protocols or stackers; requires a milligram-accurate scale; no excipients or additives; not recommended for beginners unfamiliar with powder dosing
As an Amazon Associate we earn from qualifying purchases. C15 products vary widely in how much pentadecanoic acid they actually contain, so check that the Supplement Facts panel lists C15 in milligrams as its own line item rather than bundling it into a fatty acid blend, and that the per-serving dose falls in the 100 to 300 mg range used in published research.
A Note on the Evidence
The evidence base for C15 is early-stage, with most human data coming from small, short trials conducted by researchers affiliated with the commercial developer of Fatty15; independent large-scale replication is still needed. Anyone with cardiovascular disease, metabolic conditions, pregnancy, or who takes prescription medications should consult a qualified healthcare provider before adding any fatty acid supplement to their regimen.
Frequently Asked Questions
Who discovered C15 as a potentially important fatty acid?
Dr. Stephanie Venn-Watson and colleagues at Epitracker, drawing on their background in the U.S. Navy Marine Mammal Program, identified C15 as a differentiating health marker through metabolomic analysis of bottlenose dolphins. The finding was then pursued in human epidemiological and intervention research by the same team.
Why were dolphins used in this research?
The Navy Marine Mammal Program maintains a closely monitored dolphin cohort with decades of dietary and health data: an unusually rich longitudinal dataset. This allowed researchers to correlate dietary fatty acid composition with health outcomes in a way that would be difficult to replicate quickly in human populations.
Is C15 found in food, or do you need a supplement?
C15 occurs naturally in full-fat dairy products (butter, whole milk, aged cheese) and in the fat of ruminant animals like beef and lamb. It has been proposed that dietary intake declined in populations that shifted away from these foods following saturated-fat guidelines, but this has not been tested directly. Supplemental forms like Fatty15 are designed for people who want a concentrated source without increasing overall saturated fat intake.
Has the FDA approved C15 or Fatty15 for any health condition?
No. The FDA has not evaluated C15 for the treatment or prevention of any disease. Fatty15 is sold as a dietary supplement under general wellness positioning, not as a drug or therapeutic agent.
Is C15 supplementation safe?
The one small randomized trial of C15 alone (30 adults, 200 mg a day for 12 weeks, industry-supported) reported no significant adverse events [6]. However, the available trials are small and short, so long-term safety in diverse populations has not been fully established. As with any supplement, people with existing health conditions or who take medications should consult a healthcare provider before starting.
What does 'odd-chain fatty acid' mean and why does it matter?
Fatty acids are classified partly by the number of carbon atoms in their chain. Most dietary fats are even-chain (16, 18, 20 carbons, etc.). Odd-chain fatty acids like C15 (15 carbons) are far less common in the diet and are metabolized through slightly different pathways. This metabolic distinctiveness is part of why researchers believe odd-chain fatty acids may have different physiological effects from their even-chain counterparts.
References
- Modified fish diet shifted serum metabolome and alleviated chronic anemia in bottlenose dolphins (Tursiops truncatus): Potential role of odd-chain saturated fatty acids. PLoS One, 2020
- Increased Dietary Intake of Saturated Fatty Acid Heptadecanoic Acid (C17:0) Associated with Decreasing Ferritin and Alleviated Metabolic Syndrome in Dolphins. PLoS One, 2015
- Feeding a Modified Fish Diet to Bottlenose Dolphins Leads to an Increase in Serum Adiponectin and Sphingolipids. Frontiers in Endocrinology, 2016
- Pentadecanoic and Heptadecanoic Acids: Multifaceted Odd-Chain Fatty Acids. Advances in Nutrition, 2016
- Efficacy of dietary odd-chain saturated fatty acid pentadecanoic acid parallels broad associated health benefits in humans: could it be essential?. Scientific Reports, 2020
- Pentadecanoic Acid Supplementation in Young Adults with Overweight and Obesity: A Randomized Controlled Trial. The Journal of Nutrition, 2024
- A review of odd-chain fatty acid metabolism and the role of pentadecanoic acid (C15:0) and heptadecanoic acid (C17:0) in health and disease. Molecules, 2015
- New insights on pentadecanoic acid with special focus on its controversial essentiality: a mini-review. Biochimie, 2024
- Differences in the prospective association between individual plasma phospholipid saturated fatty acids and incident type 2 diabetes: the EPIC-InterAct case-cohort study. The Lancet Diabetes & Endocrinology, 2014
- Fatty acid biomarkers of dairy fat consumption and incidence of type 2 diabetes: a pooled analysis of prospective cohort studies. PLoS Medicine, 2018
- Biomarkers of dairy fat intake, incident cardiovascular disease, and all-cause mortality: a cohort study, systematic review, and meta-analysis. PLoS Medicine, 2021
- Can individual fatty acids be used as functional biomarkers of dairy fat consumption in relation to cardiometabolic health? A narrative review. British Journal of Nutrition, 2022
- The Cellular Stability Hypothesis: Evidence of Ferroptosis and Accelerated Aging-Associated Diseases as Newly Identified Nutritional Pentadecanoic Acid (C15:0) Deficiency Syndrome. Metabolites, 2024
- Molecular and cellular mechanisms of pentadecanoic acid. World Journal of Biological Chemistry, 2025
- Broader and safer clinically-relevant activities of pentadecanoic acid compared to omega-3: Evaluation of an emerging essential fatty acid across twelve primary human cell-based disease systems. PLoS One, 2022
- Aging-Associated Amyloid-β Plaques and Neuroinflammation in Bottlenose Dolphins (Tursiops truncatus) and Novel Cognitive Health-Supporting Roles of Pentadecanoic Acid (C15:0). International Journal of Molecular Sciences, 2025
- Ilse G. Pranger et al. Fatty acids as biomarkers of total dairy and dairy fat intakes: a systematic review and meta-analysis. Nutrition Reviews (2018). PMID 30307550
- Viviana Albani et al. Exploring the association of dairy product intake with the fatty acids C15:0 and C17:0 measured from dried blood spots in a multipopulation cohort: Findings from the Food4Me study. Molecular Nutrition & Food Research (2015). PMID 26678873
- Li KJ et al. Evaluating the Robustness of Biomarkers of Dairy Food Intake in a Free-Living Population Using Single- and Multi-Marker Approaches. Metabolites (2021). PMID 34204298
- Vincent Ciesielski et al. Pentadecanoic acid in the French diet: Absolute quantitative assessment and contributions of dairy and non-dairy foods using a market basket approach. Journal of Food Composition and Analysis (2026). doi:10.1016/j.jfca.2026.109056
- Brian T. Steffen et al. Plasma pentadecanoic acid is modestly related to cardiovascular health in CARDIA and ARIC cohorts: observational associations without evidence of causality. Frontiers in Nutrition (2026). PMID 41743064
- Chen X et al. Lipid biomarkers for the prediction of type 2 diabetes risk, an umbrella review and updated meta-analyses of prospective observational studies. Frontiers in endocrinology (2026). PMID 42181198
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.